AstraZeneca (LON:AZN) has been given a GBX 3,800 ($52.50) price target by investment analysts at Goldman Sachs Group in a note issued to investors on Monday, February 19th. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group’s price target would indicate a potential downside of 20.25% from the stock’s current price.
Several other analysts have also commented on AZN. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Monday, October 23rd. UBS Group set a GBX 4,550 ($62.86) target price on AstraZeneca and gave the company a “neutral” rating in a research report on Monday, October 23rd. Liberum Capital reissued a “hold” rating and issued a GBX 5,000 ($69.08) target price on shares of AstraZeneca in a research report on Wednesday, November 1st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, November 1st. Finally, Kepler Capital Markets upped their price objective on AstraZeneca from GBX 5,200 ($71.84) to GBX 5,250 ($72.53) and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (LON AZN) traded down GBX 18 ($0.25) during trading on Monday, hitting GBX 4,765 ($65.83). The stock had a trading volume of 1,547,547 shares, compared to its average volume of 2,310,000. The firm has a market cap of $60,110.00 and a PE ratio of 2,836.31. AstraZeneca has a fifty-two week low of GBX 4,260 ($58.86) and a fifty-two week high of GBX 5,520 ($76.26).
In related news, insider Philip A. J. Broadley purchased 415 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were bought at an average price of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
TRADEMARK VIOLATION NOTICE: “AstraZeneca (LON:AZN) Given a GBX 3,800 Price Target at Goldman Sachs Group” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/14/goldman-sachs-group-reiterates-gbx-3800-price-target-for-astrazeneca-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.